Default company panoramic image

Respira Therapeutics, Inc.

Respira is inhaled pharmaceutical company targeting opportunity in the field of pulmonary arterial hypertension with a risk-reduced development approach.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Albuquerque, NM, US
  • Currency USD
  • Founded October 2010
  • Employees 5
  • Website

Company Summary

Respira is an inhaled pharmaceutical company. Respira’s lead product is an inhalable form of an off-patent oral drug for the treatment of pulmonary arterial hypertension (PAH), a deadly medical condition with no current cure. This breakthrough inhaled therapy for PAH delivered by Respira’s AOS-DPI device at a much lower dose than current oral therapies, will result in a more effective direct lung treatment at a much lower nominal dose.


  • 365e54b8 6db1 49af 8a63 0cba342033d6
    President & CEO

    Bob has an extensive background in the medical technology field from his 30+year career as a senior Pfizer executive, founder, and operating manager of multiple life science technology startups, and as a venture capital accelerator/ incubator manager and investor. He was the early CEO of Aerogen, Inc., an early-stage inhaler company, and has also served as CEO and/or Board member of one (1) public and nine (9) venture capital financed start-ups.

  • Default avatar
    Andy Clark, Ph.D.
    Vice President and CTO

    Andy is a world recognized expert in respiratory drug development and contributed to three of the most novel inhalation products. He served as CTO of Inhale Therapeutics/Nektar, developer of Exubera inhaled insulin, and more recently as CTO and site head at the California facility of Novartis, where he was responsible for the Tobi Podhaler, inhaled tobramycin for Cystic Fibrosis. Andy is a graduate of Loughborough University of Technology, U.K.

  • Default avatar
    Hugh Smyth, Ph.D.
    Consulting CSO

    Hugh is the co-inventor of the Respira DPI technology and a thought leader in pulmonary drug delivery science. He is currently an Associate Professor of Pharmaceutics at the University of Texas at Austin, College of Pharmacy. Hugh is also Adjunct Associate Scientist at Lovelace Respiratory Research Institute in Albuquerque, New Mexico.

  • Matt is a co-founder and partner of CFO Connection, a firm that has worked with over 100 venture-backed and small-cap public firms over the last 12 years. He held the top financial position at ACLARA BioSciences that achieved an ultimate market capitalization of over $2B and BioLumin which was sold to Molecular Dynamics. Matt received a BS in Business from the University of Southern California and an MBA from Santa Clara University.


  • Default avatar
    DLA Piper

Previous Investors

  • Default avatar
    Sun Mountain Capital -
    Brian Birk, Managing Partner
    Default avatar
    Cottonwood Technology Fund -
    David Blivin - Managing Partner